Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine

被引:26
|
作者
Hynninen, V-V [1 ,2 ]
Olkkola, K. T. [2 ]
Bertilsson, L. [3 ]
Kurkinen, K. [4 ]
Neuvonen, P. J. [4 ]
Laine, K. [1 ]
机构
[1] Turku Univ, Turku Univ Hosp, Dept Pharmacol, Drug Dev & Therapeut, FIN-20520 Turku, Finland
[2] Turku Univ Hosp, Dept Anesthesiol Intens Care Emergency Care & Pai, FIN-20520 Turku, Finland
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Div Clin Pharmacol, Stockholm, Sweden
[4] Univ Helsinki, Helsinki Univ Hosp, Helsinki, Finland
关键词
D O I
10.1038/sj.clpt.6100311
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study investigated the effect of terbinafine and voriconazole on the pharmacokinetics of venlafaxine in healthy volunteers. Plasma concentrations of venlafaxine and O-desmethylvenlafaxine (ODV) were measured after ingestion of 75mg venlafaxine without pretreatment (control), after terbinafine pretreatment, or after voriconazole pretreatment. During the terbinafine phase, the area under the plasma concentration-time curve (AUC((0-infinity))) of venlafaxine was on average 490% (P < 0.001) and that of ODV 57% (P < 0.001) of the corresponding control value. Terbinafine decreased the AUC((0-infinity)) ratio of ODV over venlafaxine by 82% (P < 0.001). Voriconazole slightly increased the sum of AUC((0-infinity)) of venlafaxine plus AUC((0-infinity)) of ODV (active moiety) by 31% (P < 0.001). The most likely mechanism for the interaction between terbinafine and venlafaxine is the inhibition of CYP2D6-mediated O-demethylation of venlafaxine, whereas the minor effects of voriconazole are probably due to the inhibition of CYP3A4-, CYP2C9-, or CYP2C19-mediated metabolism of venlafaxine.
引用
收藏
页码:342 / 348
页数:7
相关论文
共 50 条
  • [21] PHARMACOKINETICS OF TERBINAFINE IN THE NAIL
    FINLAY, AY
    BRITISH JOURNAL OF DERMATOLOGY, 1992, 126 : 28 - 32
  • [22] Sex Differences in Antidepressant-Like Effect of Escitalopram and Venlafaxine
    Manli Feng Wang
    Lu Tian
    Shikai Wang
    Yong Wang
    undefined Xu
    Neurochemical Journal, 2024, 18 (4) : 835 - 843
  • [23] UNHAPPY HEARTS WITH THE ANTIDEPRESSANT VENLAFAXINE
    Sopi, Bujana Batusha
    Yonekawa, Keiko
    Bernheim, Jasminka
    Caselli, Stefano
    Schmied, Christian
    Lam, Anna
    Hammer, Helene
    Jost, Christine Attenhofer
    SWISS MEDICAL WEEKLY, 2024, 154 : 63S - 64S
  • [24] Venlafaxine: a new class of antidepressant
    Hardy, J
    Argyropoulos, S
    Nutt, DJ
    HOSPITAL MEDICINE, 2002, 63 (09): : 549 - 552
  • [25] Overdose of venlafaxine - A new antidepressant
    Adesanya, A
    Varma, SL
    MEDICAL JOURNAL OF AUSTRALIA, 1997, 167 (01) : 54 - 54
  • [26] Antidepressant therapy with milnacipran and venlafaxine
    Mansuy, Lucilla
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 17 - 22
  • [27] Inhibitory Effect of Apigenin on Pharmacokinetics of Venlafaxine in vivo and in vitro
    Zhan, Yun-yun
    Liang, Bing-qing
    Gu, Er-min
    Hu, Xiao-xia
    Lin, Dan
    Hu, Guo-xin
    Zheng, Zhi-qiang
    PHARMACOLOGY, 2015, 96 (3-4) : 118 - 123
  • [28] Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine
    Troy, SM
    Parker, VP
    Hicks, DR
    Pollack, GM
    Chiang, ST
    JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (10): : 954 - 961
  • [29] Antidepressant options: Venlafaxine in perspective
    Thase, ME
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (03) : S10 - S18